Exelixis Inc
EXEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.08B
Close$
$160.22
155% upside
Current Fair Value
155% upsideUndervalued by 155% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.08 Billion |
|---|---|
| Enterprise Value | $15.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.88 |
| Beta | 0.42 |
| Outstanding Shares | 250,808,000 |
Return
| Return on Equity | 33.42% |
|---|---|
| Return on Assets | 24.70% |
| Return on Invested Capital | 35.94% |
Valuation & Multiples
| P/E Ratio | 18.19 |
|---|---|
| PEG | 123.64 |
| Price to Sales | 8.98 |
| Price to Book Ratio | 8.98 |
| Enterprise Value to Revenue | 8.69 |
| Enterprise Value to EBIT | 20.82 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.85
Average shareholder expectationRevenue Estimate
$636.40 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.88
Average shareholder expectationRevenue Estimate
$646.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 81.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 104.12% |
|---|---|
| Total Invested | $12.38M▼ 99.91% |
| Investors Holding | 26▼ 753.00% |
ESG Score
No data
About Exelixis Inc
1,077 employees
CEO: Michael Morrissey Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company m...